H.C. Wainwright analyst Yi Chen moved Nemaura Medical’s rating to under review following the fiscal Q2 report ahead of the Nasdaq hearing.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NMRD:
- Nemaura launches direct to consumer offering of metabolic health program
- Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
- Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.
- Nemaura Medical appoints Nikolai Rozanov as strategic adviser in AI